Vertex Pharmaceuticals (VRTX) Long-Term Debt Issuances (2009 - 2021)

Vertex Pharmaceuticals' Long-Term Debt Issuances history runs 9 years deep, the most recent figure standing at $10.0 million for Q4 2021.

• In Q4 2021, Long-Term Debt Issuances rose 114.68% year-over-year to $10.0 million; the TTM figure through Sep 2022 stood at $10.0 million (down 42.06% YoY), while the FY2021 annual figure was $22.6 million, up 69.92% from the prior year.
• Long-Term Debt Issuances was $10.0 million for Q4 2021 at Vertex Pharmaceuticals, up from $1.0 million in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $30.0 million in Q4 2017 to a low of $1.0 million in Q3 2021.
• Historically, Long-Term Debt Issuances has averaged $7.2 million across 5 years, with a median of $5.3 million in 2017.
• The sharpest annual moves came in 2018 and 2021: Long-Term Debt Issuances sank 73.78% in 2018, then soared 114.68% in 2021.
• A 5-year view of Long-Term Debt Issuances shows it stood at $30.0 million in 2017, then tumbled by 73.78% to $7.9 million in 2018, then increased by 14.52% to $9.0 million in 2019, then plunged by 48.23% to $4.7 million in 2020, then jumped by 114.68% to $10.0 million in 2021.
• The last three Long-Term Debt Issuances figures came in at $10.0 million (Q4 2021), $1.0 million (Q3 2021), and $8.0 million (Q2 2021), per Business Quant data.